Research programme: tuberculosis therapies - ChemDiv/Institut Pasteur Korea
Latest Information Update: 15 Apr 2009
At a glance
- Originator ChemDiv; Institut Pasteur Korea
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Tuberculosis
Most Recent Events
- 15 Apr 2009 Preclinical development is ongoing in USA and South Korea